Portland, OR -- (SBWIRE) -- 09/21/2017 -- Saxagliptin is an anti-diabetic drug that is taken orally. It is majorly used for type 2 diabetes. The drug is commercially available under the trade name Onglyza.

Access full summary at: https://www.alliedmarketresearch.com/saxagliptin-market

The Global Saxagliptin Market is driven by factors such as increasing incidence of diabetes, growing risk factors such as changing lifestyle, reduced physical exercise that lead to diabetes, complexities in alternative therapies for diabetes, and high obesity. However, a strict regulatory framework for diabetic drugs and adverse effects of saxagliptin such as upper respiratory tract infection, urinary tract infection, and headache will restrain the market growth. Innovative R&D activities in the field of diabetes therapeutics and growth opportunities in the emerging economies of Asia-Pacific and LAMEA will provide growth opportunities for the market growth.

Request TOC and Sample Report: https://www.alliedmarketresearch.com/request-toc-and-sample/4130

Key players that operate in the market include Bristol-Myers Squibb Company and AstraZeneca plc.

Saxagliptin Market Key Segments:
By Dosage
- 2.5 mg
- 5 mg

By Region
- North America
o U.S.
o Canada
o Mexico

- Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe

- Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific

- LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

Purchase this Report: https://www.alliedmarketresearch.com/checkout/791222